Grants for Independent School Districts

The purpose of this notice of funding opportunity (NOFO) is to invite applications for the Centers for Research in Emerging Infectious Diseases (CREID) Network Coordination Center (CC). The CREID Network, comprised of all recipients under this NOFO and the companion NOFO [insert NOFO number here], serves to expand knowledge on re-emerging and emerging infectious diseases (re/EIDs) around the globe where outbreaks are most likely to occur while developing expertise, capacity, and readiness to address outbreak-related research. The CC will serve to advance, facilitate, and coordinate select scientific, data and resource management, communication, administrative, and leadership efforts during both outbreak and non-outbreak periods among the CREID Networks centers and stakeholders in a collaborative and cooperative fashion.

The purpose of this notice of funding opportunity (NOFO) is to invite applications for Research Centers (RC) to support the Centers for Research in Emerging Infectious Diseases (CREID) Network. The CREID network serves to expand knowledge on re-emerging and emerging infectious diseases (re/EIDs) around the globe where outbreaks are most likely to occur. Multi- and inter-disciplinary teams of domestic and international investigators will conduct innovative, collaborative One Health (approach that recognizes the health of humans is interconnected with that of animal health and the shared environment) based research projects and will mount a rapid and effective research response to outbreaks through coordination, collaboration, and cooperation across the CREID Network.

The Volunteer Fire Capacity (VFC) Program is a federally funded grant program that allows California to provide local and rural fire departments with minor firefighting, training, communications and safety equipment for their volunteer firefighters. The VFC Program is not intended for major equipment (fire engines, vehicles, etc.) or Capital repairs. The VFC Program has a 50/50 match requirement which means that the applying department must be able to meet the intended grant award, dollar for dollar. Awards for departments are set at a minimum of $500 with a maximum of $20,000. Amounts may be adjusted based on the grant funding available. For additional information please contact Megan Esfandiary at Megan.Esfandiary@fire.ca.gov or Bryan Giambrone at Bryan.Giambrone@fire.ca.gov.

This funding opportunity provides financial support for researchers developing innovative, non-opioid treatments for various types of pain, with a focus on early-stage studies and collaboration with underrepresented populations.

The D.E. & Jane Clark Fund, established by the Oregon Community Foundation in 2013, is dedicated to supporting the general operations of nonprofits within Baker County and the town of North Powder. This fund focuses on charitable purposes, targeting organizations that contribute positively to these areas. The grant program offers financial support with an average grant size of $2,500, and considers applications from nonprofits with 501(c)(3) status, churches, and schools. Eligible proposals undergo a committee review process, with grants awarded during the fall season. The application window is open annually from June 1 to July 15, strictly disallowing multiyear funding requests. Applicants must use the MyOCF portal for submission, with required attachments including IRS 501(c)(3) tax-exempt status letters and organizational financial documents. Grant sizes typically range between $2,000 and $10,000. Grant renewed every year. Grant annual opening/closing deadline: June 1st to July 15th

The Illinois EPA is seeking proposals for projects aimed at addressing nonpoint source (NPS) pollution to enhance the quality of Illinois' surface and groundwater. Funded through the Clean Water Act's Section 319(h), this program supports the development and implementation of watershed-based planning projects. These projects may include creating new watershed-based plans, updating existing plans, providing technical assistance for NPS pollution control, and conducting environmental and social indicator monitoring. The goal is to prevent, eliminate, or reduce water quality impairments through strategic planning and community engagement. Grant renewed every year.

This funding opportunity supports researchers with a doctorate to conduct innovative studies that address and reduce racial disparities in education across various settings.

The Illinois Environmental Protection Agency (Illinois EPA) offers the Section 319(h) Grant Program to address nonpoint source (NPS) pollution affecting Illinois’ water resources. This program, funded through the Clean Water Act, supports projects that prevent, eliminate, or reduce water quality impairments caused by NPS pollution. Prioritized projects include those implementing approved watershed-based plans or Total Maximum Daily Load (TMDL) Implementation Plans, with activities ranging from BMP implementation to monitoring and outreach efforts. The program encourages applications that demonstrate a comprehensive approach to NPS pollution control and offer sustainable environmental benefits. Grant renewed every year.

This grant provides unrestricted funding to nonprofit organizations, educational institutions, and governmental entities in Ellis, Rooks, and Trego counties in Kansas to support community projects that enhance quality of life.

Under the broader Program Enhancement Projects for Adult Education, Section 225 targets corrections education and education for other institutionalized individuals in Connecticut. This initiative seeks to provide educational services to those likely to leave correctional institutions within five years, aiming to enhance their literacy, employment, and reintegration prospects. It emphasizes the importance of basic skills and literacy for effective societal participation. Funded through the Workforce Innovation and Opportunity Act (WIOA), the project promotes collaboration to meet the educational needs of this specific population, with a commitment to multi-year funding that spans from fiscal year 2025 to 2028. Grant renewed every year. It will be a 4-year program ( last application probably around May 2027)

Under the broader Program Enhancement Projects for Adult Education, Section 243 focuses on Integrated English Literacy and Civics Education (IELCE). This program supports English language learners in improving their literacy and understanding of American civics, aiming for better integration, employment, and educational opportunities. Eligible providers are encouraged to propose projects that combine IELCE educational services with integrated education and training (IET), reflecting the Workforce Innovation and Opportunity Act’s (WIOA) objectives. This funding opportunity, spanning fiscal years 2025 through 2028, promotes collaborations to fulfill the educational needs of English language learners in Connecticut. Grant renewed every year. It will be a 4-year program ( last application probably around May 2027)

This fund provides financial support for public health initiatives that promote healthy living and preventative health measures in Ellis, Rooks, and Trego Counties, Kansas.

The Program Enhancement Project for Adult Education, as part of the AEFLA Section 231 Comprehensive Adult Education Services, aims to expand and enhance educational programs for adults in Connecticut. With an emphasis on improving basic skills and literacy, the project facilitates effective participation in society and the workforce. It supports a variety of activities including adult literacy, workplace education, family literacy, and English language acquisition, among others. This initiative, funded through the Workforce Innovation and Opportunity Act (WIOA), encourages collaborations to avoid service duplication, address local needs, and ensure seamless educational transitions. The project is open for proposals from eligible agencies with the intent to award multi-year grants, ensuring sustained impact from fiscal year 2025 through 2028. Grant renewed every year. It will be a 4-year program ( last application probably around May 2027)

The purpose of this Notice Of Funding Opportunity (NOFO) is to solicit applications on the optimization and characterization of technologies and assays with the potential for utilization and adoption in regulatory submissions of genome editing therapeutics. The NIH Somatic Cell Genome Editing (SCGE) Program is funded through the NIH Common Fund, which supports cross-cutting programs that are expected to have exceptionally high impact. All Common Fund initiatives invite investigators to develop bold and innovative approaches to address problems that may seem intractable or to seize new opportunities that offer the potential for transformation of research processes. The simplicity and broad applicability of targeted and programmable genome editing approaches, including but not limited to those based on CRISPR-Cas9, raise the possibility of a fundamentally new way to treat a variety of genetic diseases. However, many challenges need to be overcome before such techniques could be widely used in the clinic. To maximize the potential of genome editing technology, the SGCE program was developed to accelerate the translation of genome editing technology into clinical applications. Based on input received from stakeholders from academia, industry, and regulatory agencies, as well as the substantial progress in the field of genome editing since the launch of the first five-year phase of the SCGE program, the second five-year phase of SCGE will focus on translating and accelerating safe and effective somatic cell genome editing therapeutics into the clinic. Specifically, SCGE Phase 2 will support the following initiatives: 1) Technologies and Assays for Therapeutic Genome Editing INDs; 2) IND-enabling Studies of Somatic Genome Editing Therapeutic Leads; 3) IND-enabling and Platform Clinical Trials of Somatic Genome Editing for Multiple Diseases and 4) Somatic Cell Genome Editing Translational Coordination and Dissemination Center (TCDC). The SCGE Program will involve collaborative research by a consortium of award recipients with differing expertise to develop, optimize and demonstrate improved candidate genome editing therapeutics as treatments for human disease. Recipients from all four SCGE program components will form a consortium, governed by a steering committee of investigators and NIH staff that will develop consensus policies and procedures for Consortium-wide activities such as data and resource sharing. Collectively, these initiatives are intended to substantially expand the number of genetic diseases treated by in vivo genome editing, ultimately allowing this technology to achieve its potential as a therapeutic platform to treat genetic disease. Program Formation and Governance The awards funded under this NOFO will be cooperative agreements (see Section VI.2. Cooperative Agreement Terms and Conditions of Award). Close interactions among the recipients and NIH will be required to maintain this complex program. The whole SCGE Program governance will rest with the SCGE Program Steering Committee in collaboration with NIH Program Officials, with advice from Program Consultants providing critical scientific and managerial insights, and subject to oversight by the NIH SCGE Working Group. The NIH SCGE Working Group consists of NIH Programmatic Staff from multiple Institutes and Centers of the NIH as well as the Office of the Director. This group will be primarily responsible for the stewardship of the SCGE Program. The SCGE Working Group is co-chaired by the Director of the National Center for Advancing Translational Sciences (NCATS) and the Director of the National Institute for Neurological Disorders and Stroke (NINDS). It reports to the Directors of the Office of Strategic Coordination/Common Fund and the Division of Program Coordination, Planning, and Strategic Initiatives for final funding decisions. Research Objectives The purpose of this 3-year U01 NOFO is to support the optimization and evaluation of IND-enabling technologies and assays to help accelerate the clinical development and evaluation of novel somatic cell genome editing therapeutics to treat a broad array of rare and common diseases. Examples of technologies and assays that would be responsive to this NOFO include those for Chemistry, Manufacturing and Controls (CMC), potency, pharmacology/toxicity, detection and measurement of on/off-target effects, immune responses, and cell tracking studies. Applicants should have an IND-enabling technology or assay to be optimized, with supportive preliminary data, at the time of submission. Projects should focus on further development and rigorous characterization of the technology and/or assay for utilization and adoption in regulatory submissions. This NOFO is intended to bring assays to the point where they could be integrated with future clinical trials/studies. Research Scope This program will support the optimization, refinement, and establishment of acceptability criteria of technologies and assays that will provide data on the efficacy and safety of somatic cell genome editing technologies and delivery systems in future regulatory submissions. In Investigational New Drug Applications (INDs) submitted to the U.S. Food and Drug Administration (FDA), sufficient CMC information should be provided to assure safety, identity, quality, purity, and strength (including potency) of the investigational product entering clinical trials. CMC activities include the establishment of manufacturing processes and product characteristics, as well as defining product testing methods to ensure that the product is safe, effective, and consistent between batches. To guide the CMC development plan, it is important to establish the Critical Quality Attributes (CQAs), a set of criteria to which a drug product should conform to be considered acceptable for its intended use. Establishing acceptable CQAs for genome editing therapeutics can be challenging due to the biological complexity of the products. Nevertheless, the risk associated with genome editing therapies can be reduced by developing appropriate analytical procedures and assays to help define suitable CQAs and ensure high-quality clinical products that meet the quality requirements for nonclinical and clinical trial materials. Process control techniques developed for protein drug production are not always applicable to cell and gene therapies. While a few in vivo somatic cell genome editing therapeutics have entered the clinic targeting the liver and eye, a comprehensive suite of technologies and assays to help define the CQAs of the genome editing product(s) have yet to be generated. Some examples of CMC challenges during the development of genome editing products include suitable potency assays to demonstrate relevant biological activity and to help determine dosage, pertinent assays to inform editing-related immunogenicity, safety and efficacy, manufacturing procedures suitable for scale-up for a multifaceted product, and other optimized bioanalytical assays to fulfill CMC-related activities. A combination of assays may be required when a single assay may not provide adequate CMC data due to a complex mechanism of action or multiple activities of a preliminary therapeutic agent. To support the clinical advancement and regulatory approval of the ever-increasing number of genome editing therapeutics, there is a need for appropriate fit-for-purpose CMC and analytical methodologies to be optimized and qualified for eventual implementation into genome editing therapeutic programs as these programs transition from research into clinical stages. Also in 2023, the FDA Modernization Act 2.0 permits the utilization of new approach methodologies (NAMs) to animal testing, including non-animal or human biology-based test methods, such as cell-based assays, microphysiological systems, or bioprinted or computer models to predict drug toxicity, metabolism, and other absorption, distribution, metabolism, and excretion (ADME) properties. NAMs can now be used to seek FDA exemptions for assessing drug safety and effectiveness during the preclinical phase. Some applicable assays have been developed by investigators in academic laboratories or small biotechnical companies for research purposes but require adaptation and/or comprehensive analysis to meet regulatory requirements during the review of clinical products. Applications responsive to this NOFO will fill this gap as these technologies and assays are critical during preclinical development and the manufacturing process, and would impact product quality, safety and efficacy during clinical application. Successful assays and associated protocols will be shared with the broader community via the Translational Coordination and Dissemination Center (TCDC) and SCGE Toolkit that will be the primary output of this collaborative Common Fund-sponsored program. Examples of product and process characterization assays supported by this NOFO include, but are not limited to: Technologies that enable more informative assessment of patient adaptive and/or innate immune (immunogenicity) responses to genome editors and vectors during clinical trials, including the presence or development of anti-drug antibodies, potential biological consequences, and whether those responses change over time or in response to redosing New approach methodologies that complement traditional animal research, including microphysiological systems, organoids, and other 3- dimensional cell models, that recapitulate critical aspects of normal human physiology and provide quantifiable and predictive measurements of genome editing effects Computer-based technologies, for example artificial intelligence or machine learning, for generating predictive models of individual or population-based biological response(s) to genome editing-based intervention Technologies to detect on and off-target editing in gene-edited animals (or humans) in a non-invasive manner, including but not limited to the use of cell-free DNA obtained from blood or other tissue compartments that can be readily accessed non-invasively (e.g. saliva, exhaled breath condensate, urine, stool) Methods to assess or predict the potential clinical impact of undesired off-target effects, including but not limited to cytotoxicity, genotoxicity, mutagenicity and tumorigenicity potential In vitro and in vivo assays for clinically relevant evaluation of the pharmacokinetic and pharmacodynamic properties of a genome delivery or editing reagent, including durability of editing, bioavailability, bioactivity, cell/tissue specificity, and/or dose-prediction in clinical trials Potency assays to assess specificity and sensitivity measurements of the functionality and efficiency of genome editing product, including vector infectivity and identity, editor activity, and other parameters as appropriate Process development technologies for scale-up and cGMP manufacturing of genome editing products Bioanalytical methods for final product identity and potential contamination Technologies for tracking and monitoring of genome editing therapies in vivo, which may include amongst others, in utero therapeutic products Applications addressing the following topics will be deemed non-responsive and will not be reviewed: Exploratory research for new technology development that lack supporting unpublished and/or preliminary data Assays that are not applicable to genome editing INDs Discovery or development of new genome editing therapeutic products Assays/technologies for non-somatic cell editing Projects proposing clinical trials Technologies that can be broadly applicable to more than one genome editing therapeutic product and/or indication are encouraged Funds from the NIH will be made available through the U01 cooperative agreement award mechanism. Awards will be up to 3 years in duration and will include milestones to evaluate progress. During the initial two years of funding, it is expected that investigators will complete the necessary studies to establish an assay profile and performance criteria (Accuracy [Relative], Analytical Measurement Range, Parallelism, Precision, Selectivity, Specificity, and Stability, as applicable) of sufficient quality for the likely utilization of the technology or assay to support IND-submission of genome editing therapeutic products. As part of the NIH SCGE Consortium, Consortium-generated animal and/or human samples from genome-editing therapeutic studies are expected to become available, and applicants are encouraged to collaborate with other SCGE Consortium members to help evaluate the utility and performance of the assay(s). It is anticipated that in the remainder of the award period, projects will continue to perform assay optimization and further define the analytical parameters using relevant samples, including samples from other consortium members as scientifically appropriate. NIH's Interest in Diversity Every facet of the United States scientific research enterprise—from basic laboratory research to clinical and translational research to policy formation–requires superior intellect, creativity and a wide range of skill sets and viewpoints. NIH’s ability to help ensure that the nation remains a global leader in scientific discovery and innovation is dependent upon a pool of highly talented scientists from diverse backgrounds who will help to further NIH's mission. Research shows that diverse teams working together and capitalizing on innovative ideas and distinct perspectives outperform homogenous teams. Scientists and trainees from diverse backgrounds and life experiences bring different perspectives, creativity, and individual enterprise to address complex scientific problems. There are many benefits that flow from a diverse NIH-supported scientific workforce, including: fostering scientific innovation, enhancing global competitiveness, contributing to robust learning environments, improving the quality of the research, advancing the likelihood that underserved or health disparity populations participate in, and benefit from health research, and enhancing public trust. NIH encourages applicants to include a diverse group of scientists in their research programs, including individuals from underrepresented backgrounds (see NOT-OD-20-031, Notice of NIH’s Interest in Diversity and NOT-OD-22-019, Reminder: Notice of NIH’s Encouragement of Applications Supporting Individuals from Underrepresented Ethnic and Racial Groups as well as Individuals with Disabilities). See Section VIII. Other Information for award authorities and regulations.

Notice of Funding Opportunity summary:The United States Agency for International Development (USAID) is seeking applications for aCooperative Agreement from qualified entities to implement the Urban Health Activity. Eligibilityfor this award is not restricted.USAID intends to make an award to the applicant who best meets the objectives of this fundingopportunity based on the merit review criteria described in SECTION E of this Notice of FundingOpportunity (NOFO), subject to a risk assessment. The applicant receiving an award will be theRecipient. Eligible parties interested in submitting an application are encouraged to read thisNOFO thoroughly to understand the type of program sought, application submissionrequirements, and selection process.Activity short summary:USAID/Uganda plans to award a five-year Cooperative Agreement to enhance health systemresilience and improve the survival and well-being of the residents of Kampala city, Mukono, andWakiso districts (hereafter referred to as the Target Districts) (the Activity). The Activity willstrengthen public and private health systems at the facility and community levels to deliverresponsive, timely, evidence-based, quality services. The Activity will strengthen maternal,newborn, and child health (MNCH); malaria; family planning (FP) / reproductive health (RH);nutrition; and Global Health Security (GHS) services in the Target Districts.

Organizations of State and Local Officials (NOSLO) Program: State Health Services and Financing to fund a national level organization with an in-depth understanding of, and experience with, providing technical assistance and support to State Medicaid Directors and other health care payment officials to assist states in leveraging HRSA programs and collaborating with Medicaid to improve access to quality health care for high need communities. Activities should include but are not limited to fostering collaborations to address maternal health disparities, bolster the health workforce, integrate behavioral health into primary care, and expand access to care for people in high need communities, such as those who live rural areas, are exiting incarceration, have HIV, and youth with unmet behavioral health needs. The successful recipient is expected to provide tailored technical assistance to State Medicaid Directors and other health care payment officials to address HRSAs priorities and maximize the benefits of and potential collaborations with HRSA programs through: Communication and information sharing between HRSA and State Medicaid Directors and other health care payment officials, and Training; data collection, sharing, and analysis; convenings, (e.g., learning exchanges on priority topics); and other activities that enable State Medicaid Directors and other health care payment officials to operate in a responsive, coordinated, and effective manner.

The FY 2025 CTE Education Career Pathway RFP, accessible through the ISBE Web Application Security (IWAS) system, is aimed at entities capable of supporting career and technical education (CTE) activities as outlined in 23 Ill. Adm. Code 256.400. The RFP for the FY 2025 planning year does not require an initial allocation or itemized budget; approved applicants will later submit an amended application with detailed financials and agreements as directed by ISBE. The application deadline is May 3, 2024, at 4:00 p.m. Grant renewed every year.

This funding opportunity supports research centers focused on improving mental health and addressing health disparities related to HIV/AIDS, particularly for early-career and underrepresented researchers.

The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) intend to publish a Notice of Funding Opportunity (NOFO) to solicit applications for large single or multisite clinical trials within the mission area of the institute. The NOFO is expected to be published in Spring 2024 with an expected application due date in Summer 2024. Only New, Resubmission and Revision applications will be eligible. This NOFO will utilize the UG3/UH3 phased cooperative agreement activity code. A UG3 milestone plan is required. Details of the planned NOFO are provided below.

The Eunice Kennedy Shriver National Institute of Child Health and Human Development intends to publish a Notice of Funding Opportunity (NOFO) to invite applications for a Data Coordinating Center to support the work of the research projects funded under the Stillbirth Research Consortium described in the companion announcement NOT-HD-24-009. This Notice is being provided to allow potential applicants additional time to develop meaningful collaborations, interdisciplinary teams, and prepare responsive applications. The NOFO is expected to be published in Summer 2024 with an expected application due date in Fall 2024. This NOFO will utilize the UM2 activity code. Details of the planned NOFO are provided below.